{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["34"],"submitter":["Cao W"],"pubmed_abstract":["Background
Therapeutic approaches to HIV-suppressed immunological non-responders (INRs) remain unsettled. We previously reported efficacy of Chinese herbal Tripterygium wilfordii Hook F in INRs. Its derivative (5R)-5-hydroxytriptolide (LLDT-8) on CD4 T cell recovery was assessed.Methods
The phase II, double-blind, randomized, placebo-controlled trial was conducted in adults patients with long-term suppressed HIV infection and suboptimal CD4 recovery, at nine hospitals in China. The patients were 1:1:1 assigned to receive oral LLDT-8 0.5 mg or 1 mg daily, or placebo combined with antiretroviral therapy for 48 weeks. All study staff and participants were masked. The primary endpoints include change of CD4 T cell counts and inflammatory markers at week 48. This study is regist"],"journal":["The Lancet regional health. Western Pacific"],"pagination":["100724"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10240372"],"repository":["biostudies-literature"],"pubmed_title":["(5R)-5-hydroxytriptolide for HIV immunological non-responders receiving ART: a randomized, double-blinded, placebo-controlled phase II study."],"pmcid":["PMC10240372"],"pubmed_authors":["Ma P","Han N","Han Y","Zuo M","Zhu B","Yu J","Liu X","Sun L","Wang M","Lu L","Li X","Li Y","Cao W","Li T","Gao L","Liu A","Wei H","Wang X","Song X","Routy JP","Lin L","Zhu T","Zhao H","Cheng J"],"additional_accession":[]},"is_claimable":false,"name":"(5R)-5-hydroxytriptolide for HIV immunological non-responders receiving ART: a randomized, double-blinded, placebo-controlled phase II study.","description":"Background
Therapeutic approaches to HIV-suppressed immunological non-responders (INRs) remain unsettled. We previously reported efficacy of Chinese herbal Tripterygium wilfordii Hook F in INRs. Its derivative (5R)-5-hydroxytriptolide (LLDT-8) on CD4 T cell recovery was assessed.Methods
The phase II, double-blind, randomized, placebo-controlled trial was conducted in adults patients with long-term suppressed HIV infection and suboptimal CD4 recovery, at nine hospitals in China. The patients were 1:1:1 assigned to receive oral LLDT-8 0.5 mg or 1 mg daily, or placebo combined with antiretroviral therapy for 48 weeks. All study staff and participants were masked. The primary endpoints include change of CD4 T cell counts and inflammatory markers at week 48. This study is regist","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 May","modification":"2026-05-29T06:35:37.2Z","creation":"2025-04-22T14:01:58.534Z"},"accession":"S-EPMC10240372","cross_references":{"pubmed":["37283977"],"doi":["10.1016/j.lanwpc.2023.100724"]}}